Recombinant Antibodies as Therapeutic Agents: Pathways for Modeling New Biodrugs

Hybridoma fusion technology, proposed by Köhler and Milstein in 1975, started major developments in the field of monoclonal antibodies (mAbs). During the following 2 decades, their high potential as laboratory tools was rapidly exploited for biotechnology and biomedical applications. Today, mAbs rep...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy biopharmaceuticals, and gene therapy, 2008-01, Vol.22 (5), p.301-314
Hauptverfasser:	Aires da Silva, Frederico, Corte-Real, Sofia, Goncalves, Joao
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Antibodies, Monoclonal - chemistry Antibodies, Monoclonal - therapeutic use Biomedical and Life Sciences Biomedicine Biotechnology Cancer Research Clinical trials Drug Development Evaluation Humans Hybridomas Molecular Medicine Monoclonal antibodies Peptide Library Pharmacotherapy Physiological aspects Protein Engineering Recombinant molecules Recombinant Proteins - chemistry Recombinant Proteins - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!